|
Start of the monitoring period n (%) or mean value ±
SD
|
|
Metformin
|
71 (44.7)
|
64 (45.1)
|
0.942
|
|
Sulfonylureas
|
15 (9.4)
|
14 (9.9)
|
0.901
|
|
Meglitinides (repaglinide/nateglinide)
|
0 (0.0)
|
0 (0.0)
|
-
|
|
Thiazolidinedions
|
3 (1.9)
|
10 (7.0)
|
0.028
|
|
Alpha-glucosidase inhibitor
|
2 (1.3)
|
1 (0.7)
|
1.0
|
|
Other*
|
1 (0.6)
|
0 (0.0)
|
1.0
|
|
Biphasic human insulin (U/day)
|
47.84 ± 20.05
|
44.75 ± 19.85
|
0.18
|
|
Biphasic human insulin (U/kg/day)
|
0.61 ± 0.27
|
0.56 ± 0.25
|
0.13
|
|
End of the monitoring period n (%)
|
|
Metformin
|
63(39.6)
|
62 (43.7)
|
0.478
|
|
Sulfonylurea
|
2 (1.3)
|
18 (12.7)
|
<0.001
|
|
Meglitinides (repaglinide/nateglinide)
|
0 (0.0)
|
6 (4.2)
|
0.009
|
|
Thiazolidinedions
|
1 (0.6)
|
7 (4.9)
|
0.021
|
|
Alpha-glucosidase inhibitor
|
1 (0.6)
|
1 (0.7)
|
1.0
|
|
Other*
|
1 (0.6)
|
2 (1.4)
|
0.604
|
|
Total insulin (glargine or biphasic plus prandial) dose (U/day)
|
50.89 ± 21.56
|
42.97 ± 21.53
|
<0.001
|
|
Total insulin (glargine or biphasic plus prandial) dose (U/kg/day)
|
0.65 ± 0.28
|
0.53 ± 0.26
|
<0.001
|
|
Change [%, 95% confidence intervals, (CI)] in the OAD and daily insulin dose between baseline and the end of the monitoring period
|
| |
%, 95% CI
|
%, 95% CI
| |
|
Metformin
|
-5.0 (-9.5, -0.4)
|
-1.4 (-6.6, 3.8)
| |
|
p-value (baseline vs end)
|
0.033
|
0.593
| |
|
Sulfonylureas
|
-8.1 (-12.9, 0.4)
|
2.8 (-3.9, 3.8)
| |
|
p-value (baseline vs end)
|
0.001
|
0.393
| |
|
Meglitinides (repaglinide/nateglinide)
|
0.0
|
4.2 (0.8, 7.6)
| |
|
p-value (baseline vs end)
|
-
|
0.014
| |
|
Thiazolinidiones
|
-1.3 (-3.0, 0.5)
|
-2.1 (-5.2, 1.0)
| |
|
p-value (baseline vs end)
|
0.157
|
0.180
| |
|
Alpha-glusidase inhibitor
|
0.0
|
0.0
| |
|
p-value (baseline vs end)
|
0.317
|
-
| |
|
Other*
|
0.0 (-1.7, 1.7)
|
1.4 (-0.5, 3.4)
| |
|
p-value (baseline vs end)
|
1.0
|
0.157
| |
|
Total insulin (glargine or biphasic plus prandial) dose (U/day)
|
3.49 (2.16, 4.82)
|
-1.78 (-5.25, -1.69)
| |
|
p-value (baseline vs end)
|
<0.001
|
0.01
| |
|
Total insulin (glargine or biphasic plus prandial) dose (U/kg/day)
|
0.04 (0.02, 0.06)
|
-0.02 (-0.07, -0.01)
| |
|
p-value (baseline vs end)
|
<0.001
|
0.007
| |
